Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Weigao Blood Purification Products CoSHSE:603014 +1.37%39 Return-on-Tangible-Equity is 6.86% as of Mar. 2026, which is 18% below its 10-year median of 8.38. GuruFocus rates SHSE:603014 with a GF Score™ of 39/100. The stock has 3 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Shandong Weigao Blood Purification Products Co ranks better than 59.29% on this metric.
SHSE:603014's Return-on-Tangible-Equity is ranked better than 59.29% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.02
vs SHSE:603014: 7.53
Shandong Weigao Blood Purification Products Co (SHSE:603014) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Equity Related Terms
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Equity Chart
Shandong Weigao Blood Purification Products Co Annual Data
SHSE:603014 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.86% mean?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Return-on-Tangible-Equity of 6.86% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. This is 18% below median its historical median of 8.38. Over the past decade, Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Equity has ranged from 7.53 to 9.74. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #309 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 40.7%.
Is Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Equity too high?
Shandong Weigao Blood Purification Products Co's current Return-on-Tangible-Equity of 6.86% is 18% below median its 10-year median of 8.38. Over the past 10 years, this metric has ranged from a low of 7.53 to a high of 9.74. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.02. Shandong Weigao Blood Purification Products Co's value of 6.86% is 70.6% above this industry median. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #309 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #309 out of 759 companies for Return-on-Tangible-Equity. This puts Shandong Weigao Blood Purification Products Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.02. Shandong Weigao Blood Purification Products Co's value of 6.86% is 70.6% above this benchmark. Historically, Shandong Weigao Blood Purification Products Co's own Return-on-Tangible-Equity has ranged from 7.53 to 9.74 over the past decade. While the company's 10-year median is 8.38 vs. the industry median of 4.02, Shandong Weigao Blood Purification Products Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.02, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Blood Purification Products Co's current Return-on-Tangible-Equity of 6.86% is 70.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Blood Purification Products Co's current Return-on-Tangible-Equity is 6.86%, which is 18% below median its own 10-year median of 8.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Return-on-Tangible-Equity of 6.86%. The current Return-on-Tangible-Equity is 6.86%, which is 18% below median its 10-year median of 8.38 and 70.6% above the Medical Devices & Instruments industry median of 4.02. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Return-on-Tangible-Equity is 6.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
